Palvella Therapeutics Inc Stock Price, News & Analysis

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company specializing in treatments for rare genetic skin diseases, has announced its upcoming participation in the Jones Healthcare and Technology Innovation Conference.

The company's Founder and CEO, Wes Kaupinen, will engage in a fireside chat on Wednesday, April 9, 2025, at 2:00 p.m. PT. The presentation will be accessible through a live webcast on the Events and Presentations section of Palvella's website (www.palvellatx.com), with the replay remaining available for approximately 90 days afterward.

Palvella focuses on developing novel therapies for serious rare genetic skin conditions that currently lack FDA-approved treatments.

Palvella Therapeutics (Nasdaq: PVLA) has announced a late-breaking oral presentation at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina (April 8-11, 2025). The presentation will focus on SELVA, a 24-week Phase 3 clinical trial evaluating QTORIN™ rapamycin 3.9% anhydrous gel for treating microcystic lymphatic malformations.

The presentation, titled 'SELVA: A Phase 3 study with a fit-for-purpose primary endpoint evaluating QTORIN™ 3.9% rapamycin anhydrous gel in the treatment of microcystic lymphatic malformations in patients 3 years of age and older,' will be delivered by Dr. Amy Paller from Northwestern University's Feinberg School of Medicine during the Free Communications VII session on April 11, 2025.

Palvella Therapeutics (NASDAQ: PVLA) reported its full year 2024 financial results and corporate updates. The company completed a merger and raised $78.9 million through a private placement from healthcare investors in December 2024. Key financial highlights include:

- Cash position of $83.6 million as of December 31, 2024, expected to fund operations into second half of 2027
- R&D expenses of $8.2 million (vs $8.8 million in 2023)
- G&A expenses increased to $5.9 million (vs $3.1 million in 2023)
- Net loss of $17.4 million or $7.83 per share

Pipeline updates: The company's lead product QTORIN™ rapamycin is advancing in two clinical trials:
- Phase 3 SELVA trial for microcystic lymphatic malformations (results expected Q1 2026)
- Phase 2 TOIVA trial for cutaneous venous malformations (results expected Q4 2025)

The company plans to expand its QTORIN™ pipeline in the second half of 2025.

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company specializing in rare genetic skin disease treatments, has scheduled its full year 2024 financial results announcement for March 31, 2025. The company will host a conference call with investors at 8:30 a.m. ET on the same day to discuss financial performance and provide a corporate update.

The presentation will include both a live webcast with slides and a dial-in option for participants. A replay of the webcast will be made available approximately 2 hours after the call concludes and will remain accessible for 90 days through the company's website.

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing therapies for rare genetic skin diseases, has announced its participation in the TD Cowen 45th Annual Healthcare Conference.

The company's management team will present on Tuesday, March 4, 2025, at 2:30 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Events and Presentations section of Palvella's website at www.palvellatx.com.

An archived replay of the webcast will remain available for approximately 90 days following the presentation. Palvella specializes in developing novel therapies for serious, rare genetic skin diseases for which there are currently no FDA-approved treatments.

Palvella Therapeutics (PVLA) announced the expansion of its Phase 3 SELVA clinical trial for QTORIN™ 3.9% rapamycin anhydrous gel to include children aged 3-5 years old, following FDA approval. The trial, previously to patients 6 years and older, evaluates the treatment for microcystic lymphatic malformations (microcystic LMs).

The company is currently enrolling approximately 40 patients in the 24-week, single-arm, baseline-controlled trial. QTORIN™ rapamycin has received Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation from the FDA. The study is supported by an FDA Orphan Products Grant of up to $2.6 million and aims to report top-line results in Q1 2026.

If successful, QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic LMs in the U.S.

Palvella Therapeutics has announced the publication of results from its Phase 2 clinical trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel for treating microcystic lymphatic malformations (microcystic LMs) in the Journal of Vascular Anomalies. The study reported that 100% of participants were rated as either “Much Improved” or “Very Much Improved” by the Clinician Global Impression of Change after 12 weeks of treatment. The FDA has previously granted QTORIN™ rapamycin Breakthrough Therapy, Fast Track, and Orphan Drug Designations for this indication.

The ongoing Phase 3 SELVA trial, which is single-arm and baseline-controlled, aims to further evaluate QTORIN™ rapamycin for microcystic LMs, with topline data expected in Q1 2026. If successful, QTORIN™ rapamycin could become the first approved therapy and standard of care in the U.S. for microcystic LMs. The Phase 2 study demonstrated nominal statistical significance across several efficacy endpoints, including clinician and patient global impression assessments. No drug-related serious adverse events were reported, indicating that QTORIN™ rapamycin was generally well-tolerated.

The publication can be accessed in the Journal of Vascular Anomalies, the official journal of the International Society for the Study of Vascular Anomalies (ISSVA). Palvella is currently enrolling approximately 40 subjects in the SELVA trial, which is supported by an Orphan Products Grant from the FDA's Office of Orphan Products Development.

Palvella Therapeutics has announced that the first patients have been dosed in the Phase 2 TOIVA clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel for treating cutaneous venous malformations (cutaneous VMs). This single-arm, baseline-controlled trial will enroll around 15 subjects across leading vascular anomaly centers in the U.S.

Cutaneous VMs are a serious genetic disease that affects over 75,000 diagnosed patients in the U.S., causing significant morbidity and functional impairment. Currently, there are no FDA-approved therapies for this condition. QTORIN™ rapamycin aims to be the first approved therapy and standard of care in the U.S. for cutaneous VMs.

The study will evaluate the safety and efficacy of QTORIN™ rapamycin, with safety assessed based on adverse events and efficacy measured by changes from baseline to week 12 in clinician and patient global impression assessments. QTORIN™ rapamycin is a topical mTOR inhibitor designed to minimize systemic exposure and adverse reactions.

The FDA granted Fast Track Designation to QTORIN™ rapamycin in April 2024, highlighting its potential to address the unmet medical needs of patients with venous malformations.

Palvella Therapeutics has completed its merger with Pieris Pharmaceuticals and will trade on Nasdaq as PVLA. The company raised $78.9 million in a private placement co-led by BVF Partners and Frazier Life Sciences. With approximately $80.0 million in cash, operations are funded into second half of 2027.

The company's lead product, QTORIN™ rapamycin, is being developed for microcystic lymphatic malformations (LMs) and cutaneous venous malformations. The drug has received FDA Breakthrough Therapy, Fast Track, and Orphan Drug Designations. A Phase 3 SELVA trial for microcystic LMs is currently enrolling approximately 40 subjects.

Post-merger, former Pieris stockholders own 11% and Palvella stockholders hold 89% of the combined company. The merger was approved by both companies' stockholders in December 2024.